ReviewWorld journal of surgical oncology2026
Advances in the molecular subtyping of gastric cancer.
Review in World journal of surgical oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Despite decades of significant progress in gastric cancer research, the prognosis remains poor because of the disease's high aggressiveness. Historically, gastric cancers were classified based on histopathology and anatomical site-criteria that inadequately support precision therapy. Advances in molecular technologies have produced multiple molecular classification schemes, among which the Cancer Genome Atlas (TCGA) and the Asian Cancer Research Group (ACRG) classifications are the most mature and widely applied. In this review, we systematically summarize molecular subtypes of gastric cancer and explore their underlying molecular mechanisms, therapeutic implications, and prognostic associations. The evidence indicates that molecular subtyping is a key basis for improving precision therapy and enhancing patient outcomes: TCGA and ACRG provide clear clinical guidance, while emerging classifications offer new directions for individualized treatment and support the clinical translation of precision oncology in gastric cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.